18-[[(1S)-1-carboxy-4-oxohexyl]amino]-18-oxooctadecanoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 18-[[(1S)-1-carboxy-4-oxohexyl]amino]-18-oxooctadecanoic acid
• 化学式: C₂₅H₄₅NO₆
• 分子量: 455.6
• InChiKey: CIMOMYDAVAOQBO-QFIPXVFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  32
• 可旋转键数：
  23
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  121
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• FGF21 ANALOGUES AND DERIVATIVES
  申请人：Garibay Patrick William

  公开号：US20130252884A1

  公开（公告）日：2013-09-26

  Novel analogues of Fibroblast Growth Factor 21 (FGF21), derivatives thereof having a modifying moiety covalently attached thereto, and pharmaceutical use of these analogues and derivatives, in particular, for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD) are described.

  本文描述了纤维母细胞生长因子21（FGF21）的新型类似物、衍生物及其上共价附着的修饰基团，以及这些类似物和衍生物的药物用途，特别是用于治疗糖尿病、血脂异常、肥胖症、心血管疾病、代谢综合征和/或非酒精性脂肪肝病（NAFLD）。
• Acylated GLP-1/GLP-2 dual agonists
  申请人：Zealand Pharma A/S

  公开号：US11395847B2

  公开（公告）日：2022-07-26

  A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.

  本发明提供了一种在 GLP-1（胰高血糖素样肽 1）和 GLP-2（胰高血糖素样肽 2）受体上具有激动剂活性的化合物，以及一种含有该化合物或其药学上可接受的盐或溶液并与药学上可接受的载体、赋形剂或载体混合的药物组合物。该化合物可用于预防或治疗肠道损伤和功能障碍、调节体重、预防或治疗代谢功能障碍等。
• Acylated GLP-1 Compounds
  申请人：Lau Jesper

  公开号：US20120295847A1

  公开（公告）日：2012-11-22

  Protracted GLP-1 compounds and therapeutic uses thereof.
• NOVEL GLUCAGON ANALOGUES
  申请人：Lau Jesper F.

  公开号：US20130035285A1

  公开（公告）日：2013-02-07

  The present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.
• Exendin-4 Derivatives
  申请人：Sanofi

  公开号：US20140206608A1

  公开（公告）日：2014-07-24

  The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.